A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions
Arthritis, Psoriatic
Interventions
DRUG

apremilast

Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium

Trial Locations (22)

1000

CHU St Pierre (César de Paepe), Brussels

Clinicque Saint-Jean Botanique, Brussels

1020

CHU Brugmann, Brussels

1170

Clin Univ de Bxl Hôpital Erasme, Brussels

1180

Private Practice, Uccle

1200

Cliniques Universiatires Saint-Luc, Brussels

1341

Private Practice, Céroux-Mousty

2170

Reumatologie Medizorg, Merksem

ZNA Jan Palfijn, Merksem

2650

UZ Antwerpen, Edegem

3000

UZ Leuven Gasthuisberg, Leuven

3500

Reuma Instituut, Hasselt

3600

Reumacentrum Genk, Genk

Reumaclinic, Genk

4000

CHU Sart-Tilman, Liège

5530

CHU UCL Mont-Godinne, Godinne

6060

GHdC Site Saint-Joseph, Gilly

8000

AZ Sint-Jan, Bruges

8300

AZ Zeno campus Knokke-Heist, Knokke-Heist

9000

UZ Gent, Ghent

9300

ASZ Aalst, Aalst

Onze Lieve Vrouw Aalst, Aalst

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03096990 - A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium | Biotech Hunter | Biotech Hunter